Goalhanger launches Goalhanger Ventures, taking an equity stake in Invisible Media and a commercial partnership with Backyard ...

Braxton Keith is well aware that he’s carrying a torch for traditional country music. He just doesn’t want fans thinking it’s a passing fancy. “It’s only gonna get bigger,” Keith says of the pivot to ...

The early 2000s were an interesting time for country music, a transition period for the genre. We had officially moved past the neon-soaked, golden era of the ’90s, but we hadn’t quite entered the ...

Labour is set to announce a new timeline on HS2 and efforts to save money after years of delays and spiralling costs ...

WASHINGTON — The U.S. Supreme Court late Monday took the unusual step of accelerating its decision that has led Louisiana lawmakers to redraw the districts from which voters will elect six ...

Family and emergency medicine physician Dr. Janette Nesheiwat discusses how artificial intelligence could help detect pancreatic cancer earlier and the FDA fast-tracking the drug daraxonrasib on ‘Fox ...

GREENVILLE, S.C. (FOX Carolina) - Psychedelics that were once considered illegal are now getting a positive push from the FDA. The agency is putting certain mental health treatments on an ultra-fast ...

Share on Pinterest The Trump administration has directed the FDA to fast-track psychedelic therapies like ibogaine to treat PTSD and other mental health disorders. farmer images/Getty Images A ...

It has been six days since President Donald Trump signed an executive order aimed at facilitating regulatory review of psychedelics that have shown potential as psychotherapeutic catalysts. As ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The U.S. Food and Drug Administration (FDA) said Friday it will ...

The Food and Drug Administration announced on Friday a series of actions intended to accelerate the use of psychedelic treatments for serious mental illness, including fast-tracking research for ...

4P004 represents a first-in-class application of GLP-1 receptor agonism in the intra-articular space, specifically targeting patients with knee osteoarthritis and synovitis who have failed multiple ...